Overview

A Phase I/II Study of AMG 510 in Combination With MVASI in Patients With Advanced, Unresectable or Metastatic KRAS G12C Mutant NSCLC With Asymptomatic Brain Metastasis

Status:
Not yet recruiting

Trial end date:
2028-06-15

Target enrollment:

Participant gender:

Summary

This is a multicenter, non-randomized, open-label, phase I/II study to evaluate the safety and tolerability of AMG 510 plus MVASI in subjects with advanced KRAS p.G12C mutant non-small cell lung cancer (NSCLC) with small, untreated brain metastases.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Criterium, Inc.

Collaborator:

Amgen